Feb. 2 at 1:49 PM
$INKT $IBRX
Clear functional overlap and potential synergy between IBRX and MiNK (INKT) at the platform level.
IBRX provides the execution engine: CAR-NK cells + IL-15 (ANKTIVA) to amplify immune killing.
MiNK (INKT) represents the orchestration layer: iNKT cells that bridge innate and adaptive immunity and help reprogram suppressed or tolerant immune environments.
Where IBRX (amplification) limits, INKT orchestration in Cold/excluded biology does its work.
Individually, each can move subsets of disease.
Together, they target complementary biology seen in cold, refractory, and heterogeneous cancers.
How these layers might ultimately combine is an open clinical question, but the systems logic for synergy is clear.
This kind of layered immune architecture aligns with the long-term goal of building a broad, next-generation cancer platform.
Together the SA Vision 2030 for Cancer Hub will have a broad platform as First in the World and nowhere else.
Here IBRX post today; https://finance.yahoo.com/news/immunitybio-launches-phase-2-chemotherapy-120000295.html
